Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1774P - Immunological-molecular profiling of chondrosarcoma (ChS)

Date

14 Sep 2024

Session

Poster session 06

Topics

Cancer Biology

Tumour Site

Bone Sarcomas

Presenters

Piotr Rutkowski

Citation

Annals of Oncology (2024) 35 (suppl_2): S1031-S1061. 10.1016/annonc/annonc1610

Authors

P. Rutkowski1, A.E. Zając1, A. Szumera-Cieckiewicz2, J. Piatkowski3, P. Teterycz1, E. Palmerini4, A. Dutour5, J. Tuziak2, M. Wagrodzki2, A. Tysarowski6, M. Gambarotti7, G. Frega4, M. Pierini4, A. Righi7, G. Magagnoli7, M. Jean-Denis8, T. Ibrahim4, J. Blay9, P. Golik3, A.M. Czarnecka1

Author affiliations

  • 1 Department Of Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 2 Department Of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 3 Institute Of Genetics And Biotechnology, University of Warsaw, 02-106 - Warsaw/PL
  • 4 Osteoncology, Bone And Soft Tissue Sarcomas And Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 5 Cell Death And Childhood Cancers Team Crcl Lyon Umr Inserm 1052 Cnrs 5286, Centre Léon Bérard, 69008 - Lyon/FR
  • 6 Cancer Molecular And Genetic Diagnostics Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 7 Department Of Pathology, IRCCS, Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 8 Department Of Biopathology, Centre Léon Bérard, 69008 - Lyon/FR
  • 9 Medicine Department, Centre Léon Bérard, 69008 - Lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1774P

Background

There is still no effective systemic treatment of ChS. ChS are considered as cold tumors with poor response to immunotherapy. Immunophenotype of ChS and characterization of immune markers, as well as molecular background of this tumors are still poorly understood. The aim of this study was both immunological and molecular profiling of ChS and correlation these features with clinical outcomes. This study may also help in selection of patients (pts) who can benefit from targeted therapy.

Methods

We enrolled 99 pts diagnosed with primary ChS (28 G1, 37 G2, 24 G3 and 10 dedifferentiated cases). For immune cells infiltrates evaluation, tissue microarrays of central and peripheral region of the tumors were prepared from formalin-fixed paraffin-embedded tissue blocks. Immunohistochemical analysis covered 20 markers defining e.g. effector T cells, antigen-presenting cells, and M1/M2 macrophages, T cells exhaustion, PD-L1 expression. Molecular profiling and tumor mutational burden were obtained by next-generation sequencing of 409 genes. Additionally, microsatellite instability was evaluated. Multiparametric analysis was performed using LASSO-based Cox regression.

Results

Median overall survival of all pts was 64.6 (95%CI: 44.2 -) months. We identified 3 different immunophenotypes among ChS pts which can be described as “cold”, “hot” and “intermediate”. The most frequently mutated genes (detected in >10% of pts) were IDH1/2, TP53, TAF1, and RNF213. The presence of IDH1/2 or TP53 mutation was significantly correlated with tumor grade and these were observed more frequently in high grade ChS. In multivariate Cox analysis the presence of “hot” (HR: 3.36, CI:1.12-10.1, p<0.05) or “intermediate” phenotype (HR: 3.07, CI:1.01-9.4, p<0.05), and IDH1 mutations (HR: 3.34, CI:1.56-7.2, p<0.01) were poor prognostic factors, as well as tumor grade and size.

Conclusions

Immune phenotypes related to higher immune cell infiltrates inside the tumor and occurrence of IDH1 mutation are independent poor prognostic factors and predict worse outcomes in ChS pts. These finding indicated that it is possible to identify a group of pts with a poor prognosis, in whom the use of immunotherapy and inhibitors of IDH-mutant could potentially provide clinical benefit.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Maria Sklodowska-Curie National Research Institute of Oncology.

Funding

Polish National Science Centre.

Disclosure

P. Rutkowski: Financial Interests, Personal, Invited Speaker, honoraria for lectures: MSD, BMS, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Pierre Fabre, Merck, Sanofi, Blueprint Medicines, Philogen; Financial Interests, Personal, Invited Speaker: Merck, Sanofi, Novartis, AstraZeneca; Financial Interests, Institutional, Research Grant, research grant for ISS: Pfizer; Financial Interests, Institutional, Funding, research grant for institution: BMS; Non-Financial Interests, Member of Board of Directors: Polish Society of Surgical Oncology; Non-Financial Interests, Member of Board of Directors, President: Polish Oncological Society. E. Palmerini: Financial Interests, Personal, Advisory Board: SynOx, Daiichi Sankyo, Deciphera Pharmaceuticals; Financial Interests, Personal, Invited Speaker: Peer View Educational. J. Blay: Financial Interests, Institutional, Invited Speaker: MSD, PharmaMar; Financial Interests, Institutional, Advisory Board: Bayer, GSK, Roche; Financial Interests, Personal, Advisory Board: Deciphera; Financial Interests, Personal, Other, member of the supervisory board. No remunerations in 2021 and 2022.: Innate pharma; Financial Interests, Personal, Member of Board of Directors: Transgene; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bayer, GSK, Novartis, OSE pharma. A.M. Czarnecka: Financial Interests, Personal, Invited Speaker: BMS, MSD, Novartis, Pierre Fabre. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.